418 related articles for article (PubMed ID: 23589547)
1. Personalizing oncology: perspectives and prospects.
Mendelsohn J
J Clin Oncol; 2013 May; 31(15):1904-11. PubMed ID: 23589547
[TBL] [Abstract][Full Text] [Related]
2. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
3. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
4. Precision oncology: an overview.
Garraway LA; Verweij J; Ballman KV
J Clin Oncol; 2013 May; 31(15):1803-5. PubMed ID: 23589545
[No Abstract] [Full Text] [Related]
5. Impact of genomics on personalized cancer medicine.
Arteaga CL; Baselga J
Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
[TBL] [Abstract][Full Text] [Related]
6. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
7. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
8. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].
Greillier L; Barlesi F
Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212
[No Abstract] [Full Text] [Related]
9. Introduction. Personalizing patient care with precision medicine.
Wujcik D; Knoop T
Semin Oncol Nurs; 2014 May; 30(2):81-3. PubMed ID: 24794081
[No Abstract] [Full Text] [Related]
10. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
11. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers and oncology: the path forward to a learning health system.
Yu PP; Hoffman MA; Hayes DF
Arch Pathol Lab Med; 2015 Apr; 139(4):451-6. PubMed ID: 25152310
[No Abstract] [Full Text] [Related]
13. Individualized targeted therapy for glioblastoma: fact or fiction?
Weller M; Stupp R; Hegi M; Wick W
Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
[TBL] [Abstract][Full Text] [Related]
14. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
[TBL] [Abstract][Full Text] [Related]
15. [Targeted therapy of a cancer patient is multiprofessional collaboration].
Ristimäki A; Kytölä S; Haglund C; Bono P
Duodecim; 2013; 129(10):1071-9. PubMed ID: 23767137
[TBL] [Abstract][Full Text] [Related]
16. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
17. Epistatic interactions and drug response.
Weigelt B; Reis-Filho JS
J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
[TBL] [Abstract][Full Text] [Related]
18. It is fascinating to see how nowadays more and more knowledge of the molecular biological characteristics of the tumour lead to individualisation with surgery, radiotherapy and systemic treatment for patients with a malignancy. Introduction.
Bartelink H
Eur J Cancer; 2011 Sep; 47 Suppl 3():xxxv. PubMed ID: 21944037
[No Abstract] [Full Text] [Related]
19. Is tailored therapy feasible in oncology?
Gasparini G; Longo R; Torino F; Gattuso D; Morabito A; Toffoli G
Crit Rev Oncol Hematol; 2006 Jan; 57(1):79-101. PubMed ID: 16337806
[TBL] [Abstract][Full Text] [Related]
20. NCI-MATCH launch highlights new trial design in precision-medicine era.
McNeil C
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
[No Abstract] [Full Text] [Related]
[Next] [New Search]
